JanssenW.E.et al., “Large-Scale Ficoll Gradient Separations Using a Commercially Available, Effectively Closed, System,” Cytotherapy, 12(3), 418–424 (May2010).
2.
SinghH.et al., “Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells,” PLOS One, 8(5), e64138 (May31, 2013).
3.
LuT.L.et al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies,” Hum. Gene Ther. Methods, 27(6), 209–218 (December2016), doi: 10.1089/hgtb.2016.120.
4.
BajgainP.et al., “Optimizing the Production of Suspension Cells Using the G-Rex ‘M’ series,” Mol. Ther. Methods Clin. Dev., 1, 14015 (May14, 2014).
5.
MockU.et al., “Automated Manufacturing of Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy Using CliniMACS Prodigy,” Cytotherapy, 18(8), 1002–1011 (August2016).
6.
HanleyP.J.et al., “Efficient Manufacturing of Therapeutic Mesenchymal Stromal Cells with the Use of the Quantum Cell Expansion System,” Cytotherapy, 16(8), 1048–1058 (August2014).
